Advanced Care Clinics Programme
Strengthen Capacity of the South African Government’s Department of Health to provide quality and sustainable care for HIV-infected patients with complicated HIV and HIV/TB treatment management, including 2nd and 3rd line and other antiretroviral therapy.
Funding Cycle: April 2014 to March 2019
This programme is funded by Centre for Disease Control (CDC) funded programme and implemented in the provinces Free State intended to strengthen the capacity of the South African government’s Department of Health to provide quality and sustainable clinical care for HIV-infected patients with complicated HIV and HIV/TB treatment management, including 2nd and 3rd line and other antiretroviral therapy, establish adequate up-referral systems to ensure relevant and timely access to regional centres for advanced clinical management of HIV/AIDS, build and support the capacity of DOH facilities at district level for the management of adult and paediatric patients with complicated disease presentations and/or with complicated HIV or HIV/TB treatment management.
(i) In Free state province, the programme is aimed to support 5 districts in FS. 3 (Motheo, Fezile Dabi and Lejweleputswa) fully supported by KI, Thabo Mofutsanyane jointly supported by the DSP Right to Care and Xhariep district (with a small patient population) where KI provided periodic support as and when required.
(ii) ACC services are supported in 2 districts in Gauteng: Ekurhuleni District and City of Johannesburg and 2 of 3 districts (Ehlanzeni & Gert Sibande) in Mpumalanga Province.
Free State (FS) Province
KI provided 12398 patients with specialist clinical care at the Advanced Clinical care centers in the districts. 211 clinicians were trained and mentored on Advanced care of HIV, TB care, 72 received in-service training, and 139 were coached on better management of clinical problems.
A total of 1164 complicated HIV cases were managed at the ACC sites by appropriately trained providers, 190 patients were initiated onto DR TB treatment regimens and a further 108 DR-TB patients traced and reinitiated onto bedaquiline therapy. The proportion of patients who had CLAT (crypto antigen test) was 8005 (achieving 98.9% of the annual target).
KI achieved 82 of the annual target for viral load uptake rate with 92% viral load suppression. The proportion of patients with persistent viral load failure started on 2nd and 3rd line regimes are 12% and 13% respectively while the proportion of patients with Rif-resistant started on appropriate therapy was 62.5% of the annual target.